Blockchain Registration Transaction Record

GeoVax Highlights MVA Vaccine Platform for Ebola and Marburg Threats

GeoVax comments on escalating Bundibugyo Ebola outbreak, highlighting MVA-based vaccine platform potential for Ebola, Marburg, and other hemorrhagic fever threats. Preclinical data shows single-dose protection.

This news matters because the ongoing Bundibugyo Ebola outbreak exposes a critical gap in global pandemic preparedness: the lack of broadly licensed vaccines for less common Ebola species. GeoVax's MVA-based platform, which has shown preclinical efficacy against multiple filoviruses, could provide a flexible, rapid-response solution for emerging threats. As governments prioritize biodefense resilience, this technology may be key to preventing future outbreaks from escalating into global health crises, directly impacting public health security and vaccine supply chains.